Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 07/06/2017 Seven people at the groundbreaking ceremony.

    Industry 4.0: Pfizer opens continuous manufacturing plant in Freiburg

    On 23rd May 2017, Pfizer officially opened a modern continuous manufacturing plant in Freiburg, thus setting a new technological standard for tablet production. A groundbreaking ceremony to inaugurate Pfizer’s new PCMM plant was held at the same time. Pfizer is investing around 50 million euros in the Freiburg facility.

    https://www.gesundheitsindustrie-bw.de/en/article/news/industry-40-pfizer-opens-continuous-manufacturing-plant-in-freiburg
  • Article - 24/05/2017 A small moss plant on a finger.

    Ralf Reski: from moss to humans

    Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
  • Press release - 06/04/2017 Mireca-Medicine-Barbara-Brunnhuberund-Francois-Paquet-Durand.jpg

    Start-up in the garage – a location with prospects

    Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germany

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/start-up-in-the-garage-a-location-with-prospects
  • Article - 23/02/2017 Photo showing the two CEOs, Dr. Frank Mathias and Michael Scholl.

    Rentschler places formulation on biopharmaceuticals production agenda with LEUKOCARE alliance

    On February 2, 2017, Rentschler Biotechnologie and LEUKOCARE announced a strategic alliance in which LEUKOCARE will become the exclusive formulation developer for the Laupheim-based contract manufacturer. Rentschler will acquire a 10% stake in LEUKOCARE, a biotech company established in 2003 and headquartered in Martinsried. On behalf of BIOPRO, Walter Pytlik spoke with the two CEOs, Rentschler’s Dr. Frank Mathias and LEUKOCARE’s Michael Scholl…

    https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-places-formulation-on-biopharmaceuticals-production-agenda-with-leukocare-alliance
  • Press release - 30/01/2017 ChemCon-Logo-Jubilaum.png

    ChemCon celebrates 20th anniversary

    ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/chemcon-celebrates-20th-anniversary
  • Dossier - 17/01/2017 Photo of the extraction procedure used to produce medicinal extracts. Two tube-shaped containers that are connected with each other by other tubes contain a brown liquid. Dr. Willmar Schwabe GmbH & Co. KG uses state-of-the-art methods to produce extracts for herbal medicines.

    Phytopharmaceuticals – fighting disease with natural substances

    Phytopharmaceuticals are herbal medicines whose efficacy is down to one or several plant substances or active ingredients. They have been used for treating diseases since time immemorial. This traditional knowledge is still the basis for many medicinal products made from plants or parts thereof. Herbal medicines have been produced in Baden-Württemberg for many generations.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances
  • Expert interview - 14/11/2016 The photo shows a green plant.

    The great untapped potential of herbal medicines

    Baden-Württemberg is home to a large number of companies that produce herbal medicines, i.e. preparations made from plant extracts rather than pure compounds. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, explains how these special extracts are placed on the market and how they differ from medicines…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-great-untapped-potential-of-herbal-medicines
  • High-tech - 20/10/2016 Man standing in front of a robot.

    Industry 4.0 in the medical technology and pharmaceutical industry sectors

    The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
  • Article - 26/09/2016 Proteinkinasen.jpg

    TuCADD: Coaching for early drug candidates

    The University of Tübingen is optimising its drug development pipeline. The TuCADD consortium provides professional help to people who want to take potential drug candidates to clinical application. The coaching involves assistance with the entire phase I drug development phase from industry experts.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tucadd-coaching-for-early-drug-candidates
  • Article - 13/09/2016 Production of white tablets.

    Catalent – galenics experts from Schorndorf

    Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.

    https://www.gesundheitsindustrie-bw.de/en/article/news/catalent-galenics-experts-from-schorndorf
  • Article - 19/07/2016 Symbolic 3D model with a T cell equipped with CAR and the relevant DNA.

    Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

    https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
  • Article - 27/06/2016 Bading_Hilmar.jpg

    A nasal spray for treating neurodegenerative diseases

    Neuroscientists from Heidelberg have created the scientific foundations for a nasal spray that can stabilise the dendrites of nerve cells, thus reducing nerve damage and brain function losses following a stroke. Prof. Dr. Hilmar Bading and his team received the 2016 German BioRegions Innovation Prize for their invention and have set up a company called FundaMental Pharma to further accelerate the development of a marketable medicinal product.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-nasal-spray-for-treating-neurodegenerative-diseases
  • Retrospective Meet & Match Pharmaceutical Process Technology - 07/04/2016 DSC_0031.jpg

    Speed dating for Pharmaceutical Process Technology – a business flirt at Bosch

    The speed dating format is no longer just a popular and simple dating method for lonely hearts, but has also become a rewarding way for establishing new business contacts and connections quickly and efficiently. BIOPRO Baden-Württemberg chose speed networking, as speed dating is called in the corporate world, for its recent Meet & Match event on pharmaceutical process technology, which took place on 15th March 2016 with the support of Bosch…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/speed-dating-for-pharmaceutical-process-technology-a-business-flirt-at-bosch
  • Article - 25/01/2016 overview.png

    And yet another biological from Biberach

    Boehringer Ingelheim is an important contract manufacturer of biopharmaceuticals that also produces proprietary drugs. We spoke with Dr. Joanne van Ryn, a Canadian pharmacologist who has been doing research at Boehringer Ingelheim’s company site in Biberach for over 20 years. Her research focuses on thrombosis, haemostasis and coagulation. She is involved in the scientific monitoring of dabigatran (Pradaxa), an oral anticoagulant that, in 2008,…

    https://www.gesundheitsindustrie-bw.de/en/article/news/and-yet-another-biological-from-biberach
  • Article - 18/01/2016 The photo shows two blister packs with tablets.

    New approaches in the life sciences industry: innovative strategies for courageous companies

    For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-avenues-in-the-life-sciences-industry-innovative-strategies-for-brave-companies
  • Press release - 16/11/2015 BP-Branchenreport-2015-R-Web.jpg

    The Baden-Württemberg healthcare industry – a strong economic power

    (Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-baden-wuerttemberg-healthcare-industry-a-strong-economic-power
  • Press release - 03/11/2015 07777_de.jpg

    CureVac raises $110 Million in a private placement

    CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
  • Article - 30/09/2015 Haworth formula of 6-deoxy-6-sulphoglucose.

    New synthesis method produces compound for use in tumour medicines

    Very few people have ever heard of the chemical compound sulphoquinovose. This natural substance is nevertheless found in a large variety of foods. Sulphoquinovose has been playing an increasing role in cancer research, which is why demand for the compound is constantly growing. With this in mind, researchers from a company called MCAT GmbH from Konstanz are working on the development a method to synthesise larger quantities of sulphoquinovose…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-synthesis-method-produces-compound-for-use-in-tumour-medicines
  • Article - 22/06/2015 Schematic showing how pharmaceutical substances travel directly from the nose to the brain by way of the olfactory nerve. From the olfactory mucosa, the substances travel up through the ethmoid bone and from there to the olfactory bulb where the fascicles of olfactory nerve end. <br />

    Through the nose directly into the brain: Biberach researchers are working on a novel way to apply pharmaceuticals

    The blood-brain barrier prevents most drugs, and large biologics in particular, from entering the brain. This physiological barrier impairs the study of central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis as well as the development of drugs. However, there is a hidden side entrance to the brain, which means that there is a way to circumvent this barrier.

    https://www.gesundheitsindustrie-bw.de/en/article/news/through-the-nose-directly-into-the-brain-biberach-researchers-are-working-on-a-novel-way-to-apply-pharmaceuticals
  • The Baden-Württemberg healthcare industry

    Baden-Württemberg – the land of startups

    Setting up an independent company is an excellent way to turn innovative life sciences solutions into successful new products and services. Baden-Württemberg is highly attractive for business startups. As one of the leading German states in the fields of healthcare and biotechnology, Baden-Württemberg has an attractive and stimulating environment for those seeking to set up their own company. Baden-Württemberg has a high density of innovative…

    https://www.gesundheitsindustrie-bw.de/en/location/start-up
  • The Baden-Württemberg healthcare industry

    The pharmaceutical industry

    Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.

    https://www.gesundheitsindustrie-bw.de/en/location/pharma
  • Article - 27/10/2014 The photo shows a drug production line.<br />

    Takeda GmbH in Singen – pharmaceutical development and production under one roof

    From stomach protection agents to drugs for the treatment of respiratory distress in preterm infants – Singen-based Takeda GmbH plays an important role as a competence centre for drugs in liquid and semi-solid dosage form within the Japanese pharmaceutical company’s global network. Besides the production of around 68 million packages per year, the company’s production site in Singen also focuses on drug development. The company’s CMC Centre…

    https://www.gesundheitsindustrie-bw.de/en/article/news/takeda-gmbh-in-singen-pharmaceutical-development-and-production-under-one-roof
  • Article - 13/10/2014 21907_de.jpg

    Data mining is likely to play an increasing role in clinical development

    Data mining still plays a minor role in the research-based pharmaceutical industry. But this is likely to change in the future. Mathematician Hans-Jürgen Lomp predicts that exploratory data analysis will be used to a greater extent in the future. Lomp is the Global Head of Statistics in Boehringer Ingelheim Pharma GmbH & Co KG’s Department of Medical Data Service and Biostatistics in Biberach.

    https://www.gesundheitsindustrie-bw.de/en/article/news/data-mining-is-likely-to-play-an-increasing-role-in-clinical-development
  • Article - 10/06/2014 Photo of junior professor Nicole Radde

    Mathematical models for predicting cellular signalling pathways

    The micrometre-sized cells in organisms are biological systems in which countless vital processes take place. However little is yet known about most of these cellular metabolic chains because they interact with each other in a complicated manner. The research carried out by junior professor Nicole Radde and her doctoral student and engineer Patrick Weber from the Institute for Systems Theory and Automated Control IST at the University of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/mathematical-models-for-predicting-cellular-signalling-pathways

Page 2 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search